- Home
- DGX
as 12-18-2024 4:00pm EST
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | SECAUCUS |
| Market Cap: | 17.5B | IPO Year: | 1996 |
| Target Price: | $168.14 | AVG Volume (30 days): | 794.0K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.44 | EPS Growth: | 11.56 |
| 52 Week Low/High: | $123.04 - $165.32 | Next Earning Date: | 01-30-2025 |
| Revenue: | $9,539,000,000 | Revenue Growth: | 2.60% |
| Revenue Growth (this year): | 7.33% | Revenue Growth (next year): | 8.70% |
Stock Insider Trading Activity of Quest Diagnostics Incorporated (DGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Nov 29 '24 | Sell | $162.70 | 35,146 | $5,731,301.51 | 38,478 | |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Nov 27 '24 | Sell | $162.64 | 33,103 | $5,395,484.41 | 96,712 | |
| DEPPE MICHAEL J | DGX | SVP, Corp. Controller & CAO | Nov 6 '24 | Sell | $153.82 | 18,755 | $2,889,122.88 | 40,130 | |
| KUPPUSAMY KARTHIK | DGX | SVP, Clinical Solutions | Oct 28 '24 | Sell | $156.92 | 1,775 | $278,525.19 | 9,734 |
Latest Quest Diagnostics Incorporated News
DGX Breaking Stock News: Dive into DGX Ticker-Specific Updates for Smart Investing
ACCESSWIRE
a day ago
Quest Diagnostics Advances Environmental Stewardship With Renewable Energy Initiatives, Waste Reduction, and ISO 14001 Certifications in 2023
MT Newswires
2 days ago
Morgan Stanley Upgrades Quest Diagnostics to Overweight From Equalweight, Adjusts Price Target to $172 From $145
Zacks
14 days ago
New Health Coaching Service on questhealth.com Set to Boost DGX Stock
PR Newswire
15 days ago
Quest Diagnostics to Speak at the 7th Annual Evercore HealthCONx Conference
PR Newswire
15 days ago
Quest Diagnostics Launches Health Coaching on questhealth.com to Help Individuals Take Control of Their Health
MT Newswires
16 days ago
Quest Diagnostics Insider Sold Shares Worth $5,395,484, According to a Recent SEC Filing
MT Newswires
16 days ago
Quest Diagnostics Insider Sold Shares Worth $5,731,302, According to a Recent SEC Filing
Insider Monkey
21 days ago
Why Quest Diagnostics Incorporated (DGX) Is One of the Most Undervalued Pot Stocks to Buy?
Compare DGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DGX Quest Diagnostics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.